Table 4

 Statistically significant correlations of per cent change in biomarker levels from baseline, with clinical end points*

TreatmentEfficacy parameterr Valuep Value
*Only statistically significant correlations are shown.
ACR20, American College of Rheumatology 20% improvement; ACR50, American College of Rheumatology 50% improvement; DAS28, Disease Activity Score based on 28 joints; ICAM-1, intracellular adhesion molecule-1; IL8, interleukin 8; SHS, Sharp score with the van der Heijde modification.
Infliximab (n = 11)
    Week 14
        ICAM-1ACR500.710.014
        IL8ACR20−0.660.027
        IL8ACR50−0.590.052
        OsteocalcinSHS−0.780.004
    Week 16
        IL8ACR50−0.740.008
Etanercept (n = 12)
    Week 14
        IL8DAS28−0.590.041
        OsteocalcinDAS280.690.011